• OPEN AN ACCOUNT
Indian Indices
Sensex
76,059.77 -331.62
( -0.43%)
Global Indices
Nasdaq
51,969.87 237.22
(0.46%)
Dow Jones
7,434.30 5.00
(0.07%)
Hang Seng
64,397.99 -2,024.61
(-3.05%)
Nikkei 225
10,738.51 99.34
(0.93%)
Forex
USD-INR
96.67 0.19
(0.20%)
EUR-INR
110.18 0.12
(0.10%)
GBP-INR
129.04 -0.01
(0.00%)
JPY-INR
0.59 0.00
(-0.04%)

EQUITY - MARKET SCREENER

Ambalal Sarabhai Enterprises Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
500009
INE432A01017
7.7619258
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AMBALALSA
22.69
248.68
EPS(TTM)
Face Value()
Div & Yield %
1.43
10
0
 

bajaj finance ltd
Aurobindo Pharma's API unit clears USFDA inspection with two observations
Jun 27,2026
The inspection, conducted between 22 June and 26 June 2026, covered the facility that manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates.

The inspection concluded with two observations. The company said it will respond to the observations within the stipulated timeline.

Aurobindo Pharma reiterated its commitment to maintaining the highest quality manufacturing standards and said it will keep the stock exchanges informed of any further developments related to the inspection.

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.

The counter advanced 1.65% to end at Rs 1,554.95 on the BSE.